Economic burden of multiple sclerosis: A systematic review of the literature

PharmacoEconomics

Volumn 28, Issue 5, 2010, Pages 363-379

  Naci, Huseyin ^a   Fleurence, Rachael ^a   Birt, Julie ^b   Duhig, Amy ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; AMBULATORY CARE; CLINICAL TRIAL; COST OF ILLNESS; DAILY LIFE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HEALTH SERVICE; HOSPITAL COST; HOSPITALIZATION; HUMAN; LABORATORY TEST; MEDICAL LEAVE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RELAPSE; REVIEW; SOCIAL INTERACTION; SYSTEMATIC REVIEW;

COST OF ILLNESS; HEALTH CARE COSTS; HUMANS; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 77951442188     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11532230-000000000-00000     Document Type: Review

References (57)

1. De Judicibus MA, McCabe MP. The impact of the financial costs of multiple sclerosis on quality of life. Int J Behav Med 2007; 14 (1): 3-11 (Pubitemid 46649585)
2. Vollmer T. The natural history of relapses in multiple sclerosis. J Neurol Sci 2007 May 15; 256 Suppl. 1: S5-13 (Pubitemid 46560640)
3. Aronson KJ. Quality of life among persons with multiple sclerosis and their caregivers. Neurology 1997; 48 (1): 74-80 (Pubitemid 27039520)
4. Yorkston KM, Johnson K, Klasner ER, et al. Getting the work done: a qualitative study of individuals with multiple sclerosis. Disabil Rehabil 2003; 25 (8): 369-379 (Pubitemid 36626491)
5. McCabe MP, De Judicibus M. The effects of economic disadvantage on psychological well-being and quality of life among people with multiple sclerosis. J Health Psychol 2005; 10 (1): 163-173 (Pubitemid 40111005)
6. Stolp-Smith KA, Atkinson EJ, Campion ME, et al. Health care utilization in multiple sclerosis: a population-based study in Olmsted County, MN. Neurology 1998; 50 (6): 1594-1600
7. Ford HL, Gerry E, Johnson MH, et al. Health status and quality of life of people with multiple sclerosis. Disabil Rehabil 2001; 23 (12): 516-521 (Pubitemid 32591124)
8. Rumrill Jr PD, Roessler RT, McMahon BT, et al. Gender as a differential indicator of the employment discrimination experiences of Americans with multiple sclerosis. Work 2007; 29 (4): 303-311
9. Auty A, Belanger C, Bouchard JP, et al. Burden of illness of multiple sclerosis: part II. Quality of life. Can J Neurol Sci 1998; 25 (1): 31-38 (Pubitemid 28210156)
10. Miltenburger C, Kobelt G. Quality of life and cost of multiple sclerosis (provisional record). Clin Neurol Neurosurg 2002; 104: 272-275
11. Pohar SL, Jones CA, Warren S, et al. Health status and health care utilization of multiple sclerosis in Canada. Can J Neurol Sci 2007; 34 (2): 167-174 (Pubitemid 47000118)
12. Pope GC, Urato CJ, Kulas ED, et al. Prevalence, expenditures, utilization, and payment for persons with MS in insured populations (provisional record). Neurology 2002; 58: 37-43
13. Gottberg K, Einarsson U, Fredrikson S, et al. Multiple sclerosis in Stockholm County: a pilot study of utilization of health-care resources, patient satisfaction with care and impact on family caregivers. Acta Neurol Scand 2002; 106 (5): 241-247 (Pubitemid 35177989)
14. Beckerman H, Van Zee IE, De Groot V, et al. Utilization of health care by patients with multiple sclerosis is based on professional and patient-defined health needs. Multiple Sclerosis 2008; 00: 1-11
15. Rice D. Cost illness studies: what is good about them? Inj Prev 2000; 6: 177-199
16. Rice D. The economic burden of musculoskeletal conditions, US, 1995. Rosemont (IL): American Academy of Orthopedic Surgeons, 1999
17. Taylor D. How much for persons with Alzheimer's disease cost Medicare? J Am Geriatr Soc 2000; 48: 639-646
18. Shiell A, Gerard K, Donaldson C. Cost of illness studies an aid to decision making? Health Policy 1987; 8: 317-323 (Pubitemid 18060163)
19. Release FRS. Foreign exchange rates. 2009 [online]. Available from URL: http://www.federalreserve.gov/releases/g5a/ [Accessed 2009 Mar 15]
20. US Department of Labor. Bureau of Labor Statistics. Consumer price index 2009 [online]. Available from URL: ftp:// ftp.bls.gov/pub/special.requests/cpi/ cpiai.txt [Accessed 2009 Mar 15]
21. Kobelt G, Berg J, Lindgren PBU, et al. Costs and quality of life of multiple sclerosis in Austria [brief record]. Eur J Health Econ 2006; 7: S14-23 (Pubitemid 46318951)
22. Taylor B, McDonald E, Fantino B, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci 2007; 14 (6): 532-539 (Pubitemid 46553791)
23. Carton H, Loos R, Pacolet J, et al. Utilisation and cost of professional care and assistance according to disability of patients with multiple sclerosis in Flanders [Belgium]. J Neurol Neurosurg Psychiatry 1998; 64 (4): 444-450 (Pubitemid 28195943)
24. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life for patients with multiple sclerosis in Belgium. Eur JHealth Econ 2006; 7 Suppl. 2: S24-33 (Pubitemid 46318946)
25. Asche CV, Ho E, Chan B, et al. Economic consequences of multiple sclerosis for Canadians. Acta Neurol Scand 1997; 95 (5): 268-274 (Pubitemid 27214475)
26. Auty A, Belanger C, Bouchard JP, et al. Burden of illness of multiple sclerosis: part I. Cost of illness. Can J Neurol Sci 1998; 25 (1): 23-30 (Pubitemid 28210155)
27. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis [provisional record]. Multiple Sclerosis 2000; 6: 91-98 (Pubitemid 30218902)
28. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: an observational study in Germany. Eur J Health Econ 2001; 2 (2): 60-68 (Pubitemid 33014731)
29. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006; 7 Suppl. 2: 514-523
30. Amato MP, Battaglia MA, Caputo D, et al. The costs of multiple sclerosis: a cross-sectional, multicenter cost-ofillness study in Italy [provisional record]. J Neurol 2002; 249: 152-163
31. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Italy. Eur J Health Econ 2006; 7 Suppl. 2: S45-54
32. Russo P, Capone A, Paolillo A, et al. Cost-analysis of relapsing-remitting multiple sclerosis in Italy after the introduction of new disease-modifying agents. Clinical Drug Investig 2004; 24 (7): 409-420
33. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in the Netherlands. Eur J Health Econ 2006; 7 Suppl. 2: S55-64
34. Matschay A, Nowakowska E, Hertmanowska H, et al. Cost analysis of therapy for patients with multiple sclerosis (MS) in Poland. Pharmacol Rep 2008; 60: 632-644
35. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Spain. Eur J Health Econ 2006; 7 Suppl. 2: S65-74
36. Casado V, Martinez-Yelamos S, Martinez-Yelamos A, et al. Direct and indirect costs of multiple sclerosis in Baix Llobregat (Catalonia, Spain), according to disability. BMC Health Serv Res 2006; 6: 143
37. Casado V, Romero L, Gubieras L, et al. An approach to estimating the intangible costs of multiple sclerosis according to disability in Catalonia, Spain. Mult Scler 2007; 13 (6): 800-804
38. Henriksson F, Jonsson B. The economic cost of multiple sclerosis in Sweden in 1994. Pharmacoeconomics 1998; 13 (5 Pt 2): 597-606
39. Henriksson F, Fredrikson S,Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a crosssectional study in Sweden. Eur J Neurol 2001; 8 (1): 27-35
40. Berg J, Lindgren P, Fredrikson S, et al. Costs and quality of life of multiple sclerosis in Sweden. Eur J Health Econ 2006; 7 Suppl. 2: S75-85
41. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in Switzerland. Eur J Health Econ 2006; 7 Suppl. 2: S86-95
42. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006; 7: S96-104
43. McCrone P, Heslin M, KnappM, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008; 26 (10): 847-860
44. Tyas D, Kerrigan J, Russell N, et al. The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value Health 2007; 10 (5): 386-389
45. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998; 4 (5): 419-425
46. O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003; 3 (1): 17
47. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007; 13 (1): 44-52
48. Murphy N, Confavreux C, Haas J, et al. Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998; 13 (5 Pt 2): 607-622
49. Sobocki P, Pugliatti M, Lauer K, et al. Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult Sclerosis 2007; 13 (8): 1054-1064 (Pubitemid 351541442)
50. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006; 77 (8): 918-926 (Pubitemid 44174075)
51. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis. Eur J Health Econ 2006; 7: S5-13 (Pubitemid 46318945)
52. Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in theUK. ValueHealth 2007; 10 (1): 54-60 (Pubitemid 46161095)
53. Akobundu E, Ju J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006; 24 (9): 869-890 (Pubitemid 44338298)
54. Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001; 19 (2): 207-213 (Pubitemid 32176473)
55. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000 May 13; 320 (7245): 1335
56. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992; 2 (1): 1-4
57. Marrie R, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 2008 Sep; 14 (8): 1091-1098